Neurocrine Biosciences, Inc. (NBIX)
Automate Your Wheel Strategy on NBIX
With Tiblio's Option Bot, you can configure your own wheel strategy including NBIX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NBIX
- Rev/Share 26.9889
- Book/Share 30.2173
- PB 4.9647
- Debt/Equity 0.1426
- CurrentRatio 3.3831
- ROIC 0.1033
- MktCap 14915820111.0
- FreeCF/Share 5.9668
- PFCF 25.1489
- PE 34.8411
- Debt/Assets 0.1004
- DivYield 0
- ROE 0.1582
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NBIX | Citigroup | -- | Buy | -- | $175 | Oct. 21, 2025 |
| Initiation | NBIX | Truist | -- | Buy | -- | $163 | July 21, 2025 |
| Initiation | NBIX | Goldman | -- | Buy | -- | $182 | July 10, 2025 |
| Upgrade | NBIX | Needham | Hold | Buy | -- | $138 | April 15, 2025 |
| Upgrade | NBIX | RBC Capital Mkts | Sector Perform | Outperform | -- | $137 | April 14, 2025 |
| Initiation | NBIX | Deutsche Bank | -- | Hold | -- | $138 | Feb. 11, 2025 |
| Resumed | NBIX | Raymond James | -- | Outperform | -- | $155 | Oct. 10, 2024 |
| Upgrade | NBIX | Piper Sandler | Neutral | Overweight | $131 | $159 | Aug. 29, 2024 |
News
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Earnings Estimates Rising for Neurocrine (NBIX): Will It Gain?
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
What Makes Neurocrine (NBIX) a New Strong Buy Stock
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Neurocrine (NBIX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Neurocrine Biosciences, Inc. (NBIX) Q3 2025 Earnings Call Transcript
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Company Participants Todd Tushla Kyle Gano - CEO & Director Matthew Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Sanjay Keswani - Chief Medical Officer Conference Call Participants Philip Nadeau - TD Cowen, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Tazeen Ahmad - BofA Securities, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Jay Olson - …
Read More
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock
Published: October 28, 2025 by: 24/7 Wall Street
Sentiment: Positive
Neurocrine Biosciences posts standout Q3 beat as INGREZZA and CRENESSITY drive 28% product sales growth.
Read More
Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Neurocrine Biosciences (NBIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Read More
GRFS or NBIX: Which Is the Better Value Stock Right Now?
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Neurocrine Biosciences, Inc. (NBIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Kyle Gano - CEO & Director Sanjay Keswani - Chief Medical Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley's Global Healthcare Conference. I'm Sean Laaman, Head of U.S. mid-cap biotech equity research here at the firm.
Read More
Neurocrine Biosciences, Inc. (NBIX) Presents At Cantor Global Healthcare Conference 2025 Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:00 PM EDT Company Participants Matthew Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Presentation Joshua Schimmer Biotech Equity Research Analyst Now we're ready to get started. All right.
Read More
GRFS or NBIX: Which Is the Better Value Stock Right Now?
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
Published: July 14, 2025 by: PRNewsWire
Sentiment: Neutral
One-year data from CAHtalyst™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia Results build upon previously reported one-year data from CAHtalyst™ Pediatric study SAN DIEGO , July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new one-year data from the CAHtalyst™ Adult study of CRENESSITY® (crinecerfont) showing that patients achieved lasting, more physiologic glucocorticoid doses, while adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained at or below baseline levels. These data complement the recently announced CAHtalyst™ Pediatric one-year results and were presented at the …
Read More
Neurocrine Biosciences: Still A Buy After 30% Uplift Since My Last Coverage
Published: July 04, 2025 by: Seeking Alpha
Sentiment: Positive
Neurocrine's core assets, INGREZZA and Crenessity, can drive strong revenue growth with robust patent protection and significant market underpenetration. The pharma's pipeline is advancing, with multiple late-stage studies in major depressive disorder and schizophrenia offering substantial upside if successful. Competition remains a risk, but INGREZZA and Crenessity face limited near-term threats; pipeline assets could add billions in value if data is positive.
Read More
CPRX vs. NBIX: Which Stock Is the Better Value Option?
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
CPRX or NBIX: Which Is the Better Value Stock Right Now?
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Neurocrine Biosciences (NBIX). But which of these two stocks is more attractive to value investors?
Read More
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Tokyo, Japan and Cambridge, UK, 3 June 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences (“Neurocrine”) has dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-'568) as a potential treatment for schizophrenia, resulting in a payment of US$15 million to Nxera (Clinical Trial ID: NCT06963034). The US$15 million payment will be fully recognized as revenue in the second quarter of 2025.
Read More
Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using multiple clinically validated scales Patients taking INGREZZA reported robust and clinically meaningful improvements in physical, social and emotional functioning Improvements were seen as early as Week 4 after initial treatment with the lowest INGREZZA dose and sustained through Week 24 Even patients with milder uncontrolled movement severity were negatively impacted by their tardive dyskinesia at baseline and demonstrated meaningful improvements in tardive dyskinesia impact with INGREZZA treatment SAN DIEGO , June 2, 2025 /PRNewswire/ -- …
Read More
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
Published: May 16, 2025 by: PRNewsWire
Sentiment: Neutral
One-Year Data Show Lasting Reductions in Glucocorticoid Doses and Improvements in Clinical Outcomes with CRENESSITY™ (crinecerfont) in Pediatric Patients with Classic Congenital Adrenal Hyperplasia SAN DIEGO , May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data from the Phase 3 CAHtalyst™ Pediatric study showing lasting reductions in glucocorticoid doses in pediatric patients with classic congenital adrenal hyperplasia who received CRENESSITY™ (crinecerfont) for up to one year. In addition, the study showed that for patients on CRENESSITY, adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained below baseline levels, despite substantially decreased glucocorticoid doses.
Read More
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
Published: May 16, 2025 by: PRNewsWire
Sentiment: Neutral
Patients Treated with INGREZZA® (valbenazine) Capsules Reported Continued Improvements in Functional and Health-Related Quality of Life Measures Findings Presented at 2025 International Society for Pharmacoeconomics and Outcomes Research Conference SAN DIEGO , May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study (NCT03891862) showing patients with tardive dyskinesia who received continued treatment with INGREZZA® (valbenazine) capsules reported improvements across functional and health-related quality of life measures. These findings complement recently announced patient-reported outcome data from the Phase 4 KINECT-PRO™ study of INGREZZA, which was the first …
Read More
GRFS or NBIX: Which Is the Better Value Stock Right Now?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
- Data Consistent Across All Patient Subgroups, Including Demographic Subgroups, by Baseline Androstenedione Levels and by Baseline Glucocorticoid Dose - Findings to be Presented at the 2025 Joint Congress of the European Society for Paediatric Endocrinology and the European Society of Endocrinology SAN DIEGO , May 8, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new results from subgroup analyses of the Phase 3 CAHtalyst™ Pediatric study. The analyses showed that, consistently across all of the different subgroups analyzed, pediatric patients with classic congenital adrenal hyperplasia maintained or improved their androstenedione levels with CRENESSITY™ (crinecerfont) while reducing glucocorticoid …
Read More
Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug
Published: May 06, 2025 by: Investors Business Daily
Sentiment: Positive
Neurocrine Biosciences shares catapulted Tuesday on "surprising commercial momentum" for its newest drug, Crenessity.
Read More
2 Pharma Stocks Staging Big Post-Earnings Moves
Published: May 06, 2025 by: Schaeffers Research
Sentiment: Neutral
Biopharmaceutical giants Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Neurocrine Biosciences Inc (NASDAQ:NBIX) are fresh out of the earnings confessional, with very different results.
Read More
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
New multimedia awareness campaign empowers people living with tardive dyskinesia to stand up to stigma and speak openly with their healthcare provider about symptoms and treatment SAN DIEGO , May 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of ConnectING with Carnie™, a multimedia awareness campaign in partnership with Grammy-nominated singer-songwriter and mental health advocate, Carnie Wilson. The campaign aims to support people struggling with the uncontrolled movements of tardive dyskinesia, an involuntary movement disorder associated with the use of antipsychotic medications, by sharing stories of courage and resilience in seeking diagnosis and treatment.
Read More
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , April 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the company's investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study in adults with schizophrenia were reported in August 2024.
Read More
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Published: April 04, 2025 by: PRNewsWire
Sentiment: Neutral
Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO , April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025.
Read More
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder Findings Presented at the 2025 Psychiatry Update Conference SAN DIEGO , March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily INGREZZA® (valbenazine) capsules. This analysis was presented at the 2025 Psychiatry Update Conference in Chicago.
Read More
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
Published: March 17, 2025 by: 24/7 Wall Street
Sentiment: Neutral
If you work in the biotech industry, you might know the name Alex Denner.
Read More
About Neurocrine Biosciences, Inc. (NBIX)
- IPO Date 1996-05-23
- Website https://www.neurocrine.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Kyle W. Gano
- Employees 1800